Time recall; future concept of chronomodulating chemotherapy for cancer

Current Pharmaceutical Biotechnology

Volumn 14, Issue 6, 2013, Pages 632-642

  Zarogoulidis, Paul ^a,b   Darwiche, Kaid ^b   Huang, Haidong ^c   Spyratos, Dionysis ^a   Yarmus, Lonny ^d   Li, Qiang ^c   Kakolyris, Stylianos ^e   Syrigos, Konstantinos ^f   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b RUHRLANDKLINIK   (Germany)

^c II Military University Hospital   (China)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^f SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Cancer; Chemotherapy; Chronomodulation; Circadian rhythm; Sleep disorders

Indexed keywords

ABC TRANSPORTER; ALKALINE PHOSPHATASE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CREATINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; MELATONIN; OPIATE; OXALIPLATIN; PACLITAXEL; SELENIUM;

ANXIETY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CIRCADIAN RHYTHM; COLORECTAL CANCER; DRUG SAFETY; EPWORTH SLEEPINESS SCALE; FATIGUE SEVERITY SCALE; HEAD AND NECK CANCER; HUMAN; INSOMNIA; KIDNEY CANCER; LEUKOCYTE COUNT; LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PITTSBURGH SLEEP QUALITY INDEX; PLEURA MESOTHELIOMA; POLYSOMNOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STRESS; TUMOR BIOPSY; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CIRCADIAN RHYTHM; DRUG CHRONOTHERAPY; HUMANS; NEOPLASMS; SLEEP DISORDERS;

EID: 84888217472     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/13892010113146660229     Document Type: Review

References (99)

1. McLeod, H. L., Cancer pharmacogenomics: early promise, but concerted effort needed. Science, 2013, 339(6127), 1563-1566
2. Domvri, K., Darwiche, K., Zarogoulidis, P., Zarogoulidis, K., Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. Transl. Lung Cancer Res., 2012.
3. Gori, B.; Ricciardi, S.; del Signore, E.; Fulvi, A.; de Marinis, F., Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert. Opin. Ther. Targets, 2012, 16 Suppl 2, S55-S60.
4. Pallis, A. G.; Georgoulias, V., Is there a standard regimen for firstline treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. Lung Cancer, 2012, 75(3), 269-274.
5. Zarogoulidis, P.; Eleftheriadou, E.; Sapardanis, I.; Zarogoulidou, V.; Lithoxopoulou, H.; Kontakiotis, T.; Karamanos, N.; Zachariadis, G.; Mabroudi, M.; Zisimopoulos, A.; Zarogoulidis, K., Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest. New Drugs, 2012, 30(4), 1628-1640
6. Zarogoulidis, P.; Chatzaki, E.; Porpodis, K.; Domvri, K.; Hohenforst-Schmidt, W.; Goldberg, E. P.; Karamanos, N.; Zarogoulidis, K., Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomedicine, 2012, 7, 1551-1572
7. Horev-Drori, G.; Cooks, T.; Bittan, H.; Lazarov, E.; Schmidt, M.; Arazi, L.; Efrati, M.; Kelson, I.; Keisari, Y., Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radiumloaded wires releasing alpha-emitting atoms. Transl. Res., 2012, 159(1), 32-41
8. Lin, X.; Gao, R.; Zhang, Y.; Qi, N.; Zhang, K.; He, H.; Tang, X., Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy. Expert. Opin. Drug Deliv., 2012, 9(7), 767-781
9. Xie, H.; Goins, B.; Bao, A.; Wang, Z. J.; Phillips, W. T., Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells. Int. J. Nanomedicine, 2012, 7, 2227-2238
10. Jia, Y.; Yuan, M.; Yuan, H.; Huang, X.; Sui, X.; Cui, X.; Tang, F.; Peng, J.; Chen, J.; Lu, S.; Xu, W.; Zhang, L.; Guo, Q., Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int. J. Nanomedicine., 2012, 7, 1697-1708
11. Hecht, J. R.; Farrell, J. J.; Senzer, N.; Nemunaitis, J.; Rosemurgy, A.; Chung, T.; Hanna, N.; Chang, K. J.; Javle, M.; Posner, M.; Waxman, I.; Reid, A.; Erickson, R.; Canto, M.; Chak, A.; Blatner, G.; Kovacevic, M.; Thornton, M., EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest. Endosc., 2012, 75(2), 332-338.
12. Trotti, A.; Colevas, A. D.; Setser, A.; Rusch, V.; Jaques, D.; Budach, V.; Langer, C.; Murphy, B.; Cumberlin, R.; Coleman, C. N.; Rubin, P., CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol., 2003, 13(3), 176-181.
13. Ihbe-Heffinger, A.; Paessens, B. J.; von Schilling, C.; Shlaen, M.; Gottschalk, N.; Berger, K.; Bernard, R.; Kiechle, M.; Peschel, C.; Jacobs, V. R., Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie, 2011, 34(5), 241-246.
14. Miaskowski, C.; Lee, K. A., Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J. Pain. Symptom Manage., 1999, 17 (5), 320-332
15. Zarogoulidis, P., Steiropoulos, P., Perantoni, E., Archontogeorgis, K., Eleftheriadou, E., Porpodis, K., Charpidou, A., G., Angelopoulou, C., Nena, E., Zarogoulidis, K., Tsara, V., Subjective sleep quality in lung cancer patients before and after chemotherapy. Thoracic Cancer, 2013, 4(2), 138-142
16. Berger, A. M., Update on the state of the science: sleep-wake disturbances in adult patients with cancer. Oncol. Nurs. Forum, 2009, 36(4), E165-77
17. Lee, K.; Cho, M.; Miaskowski, C.; Dodd, M., Impaired sleep and rhythms in persons with cancer. Sleep Med. Rev., 2004, 8(3), 199-212.
18. Hsu, C. M.; Lin, S. F.; Lu, C. T.; Lin, P. M.; Yang, M. Y., Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol., 2012, 33 (1), 149-155.
19. Jiao, L.; Duan, Z.; Sangi-Haghpeykar, H.; Hale, L.; White, D. L.; El-Serag, H. B., Sleep duration and incidence of colorectal cancer in postmenopausal women. Br. J. Cancer, 2013, 108(1), 213-221.
20. Berger, A. M.; Hertzog, M.; Geary, C. R.; Fischer, P.; Farr, L., Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors. J. Cancer Surviv., 2012, 6(3), 305-314.
21. Mazzoccoli, G.; Giuliani, F.; Sothern, R. B., Determination of whole body circadian phase in lung cancer patients: melatonin vs. cortisol. Cancer Epidemiol., 2012, 36(1), e46-e53.
22. Lengyel, Z.; Lovig, C.; Kommedal, S.; Keszthelyi, R.; Szekeres, G.; Battyani, Z.; Csernus, V.; Nagy, A. D., Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors. Tumour Biol., 2013, 34(2), 811-819.
23. Hanoun, M.; Eisele, L.; Suzuki, M.; Greally, J. M.; Huttmann, A.; Aydin, S.; Scholtysik, R.; Klein-Hitpass, L.; Duhrsen, U.; Durig, J., Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One, 2012, 7(3), e34347.
24. Mazzoccoli, G.; Piepoli, A.; Carella, M.; Panza, A.; Pazienza, V.; Benegiamo, G.; Palumbo, O.; Ranieri, E., Altered expression of the clock gene machinery in kidney cancer patients. Biomed. Pharmacother., 2012, 66(3), 175-179.
25. Elshazley, M.; Sato, M.; Hase, T.; Yamashita, R.; Yoshida, K.; Toyokuni, S.; Ishiguro, F.; Osada, H.; Sekido, Y.; Yokoi, K.; Usami, N.; Shames, D. S.; Kondo, M.; Gazdar, A. F.; Minna, J. D.; Hasegawa, Y., The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int. J. Cancer, 2012, 131(12), 2820-2831.
26. Gallion, H. H.; Brunetto, V. L.; Cibull, M.; Lentz, S. S.; Reid, G.; Soper, J. T.; Burger, R. A.; Andersen, W., Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol., 2003, 21(20), 3808-3813.
27. Relles, D.; Sendecki, J.; Chipitsyna, G.; Hyslop, T.; Yeo, C. J.; Arafat, H. A., Circadian gene expression and clinicopathologic correlates in pancreatic cancer. J. Gastrointest. Surg., 2013, 17(3), 443-450.
28. Altman, L. C.; Munk, Z.; Seltzer, J.; Noonan, N.; Shingo, S.; Zhang, J.; Reiss, T. F., A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J. Allergy Clin. Immunol., 1998, 102(1), 50-56.
29. Levi, F.; Le Louarn, C.; Reinberg, A., Timing optimizes sustained-release indomethacin treatment of osteoarthritis. Clin. Pharmacol. Ther., 1985, 37(1), 77-84
30. Buttgereit, F.; Doering, G.; Schaeffler, A.; Witte, S.; Sierakowski, S.; Gromnica-Ihle, E.; Jeka, S.; Krueger, K.; Szechinski, J.; Alten, R., Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet, 2008, 371 (9608), 205-214.
31. Miaskowski, C.; Lee, K.; Dunn, L.; Dodd, M.; Aouizerat, B. E.; West, C.; Paul, S. M.; Cooper, B.; Wara, W.; Swift, P., Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. Cancer Nurs., 2011, 34(4), 255-268.
32. Kotronoulas, G.; Wengstrom, Y.; Kearney, N., A critical review of women's sleep-wake patterns in the context of neo-/adjuvant chemotherapy for early-stage breast cancer. Breast, 2012, 21(2), 128-141
33. Dedert, E.; Lush, E.; Chagpar, A.; Dhabhar, F. S.; Segerstrom, S. C.; Spiegel, D.; Dayyat, E.; Daup, M.; McMasters, K.; Sephton, S. E., Stress, coping, and circadian disruption among women awaiting breast cancer surgery. Ann. Behav. Med., 2012, 44 (1), 10-20.
34. Le Guen, Y.; Gagnadoux, F.; Hureaux, J.; Jeanfaivre, T.; Meslier, N.; Racineux, J. L.; Urban, T., Sleep disturbances and impaired daytime functioning in outpatients with newly diagnosed lung cancer. Lung Cancer, 2007, 58(1), 139-143.
35. Kim, K. S.; Kim, Y. C.; Oh, I. J.; Kim, S. S.; Choi, J. Y.; Ahn, R. S., Association of worse prognosis with an aberrant diurnal cortisol rhythm in patients with advanced lung cancer. Chronobiol. Int., 2012, 29(8), 1109-1120.
36. Greene, M. W., Circadian rhythms and tumor growth. Cancer Lett., 2012, 318 (2), 115-123
37. Savvidis, C.; Koutsilieris, M., Circadian rhythm disruption in cancer biology. Mol. Med., 2012, 18, 1249-1260
38. Bernard, S.; Cajavec Bernard, B.; Levi, F.; Herzel, H., Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput. Biol., 2010, 6 (3), e1000712.
39. Bhatti, P.; Mirick, D. K.; Davis, S., Invited commentary: Shift work and cancer. Am. J. Epidemiol., 2012, 176(9), 760-763; discussion 764-5
40. Parent, M. E.; El-Zein, M.; Rousseau, M. C.; Pintos, J.; Siemiatycki, J., Night work and the risk of cancer among men. Am. J. Epidemiol., 2012, 176(9), 751-759
41. Grundy, A.; Tranmer, J.; Richardson, H.; Graham, C. H.; Aronson, K. J., The influence of light at night exposure on melatonin levels among Canadian rotating shift nurses. Cancer Epidemiol. Biomarkers Prev., 2011, 20(11), 2404-2412.
42. Mitra, S., Does evening sun increase the risk of skin cancer? Proc. Natl. Acad. Sci. USA, 2011, 108(47), 18857-18858.
43. Levi, F.; Okyar, A., Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert. Opin. Drug Deliv., 2011, 8(12), 1535-1541.
44. Zhao, N.; Tang, H.; Yang, K.; Chen, D., Circadian rhythm characteristics of oral squamous cell carcinoma growth in an orthotopic xenograft model. Onco. Targets Ther., 2013, 6, 41-46.
45. Aaronson, N. K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N. J.; Filiberti, A.; Flechtner, H.; Fleishman, S. B.; de Haes, J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst., 1993, 85(5), 365-376.
46. Tsara, V.; Serasli, E.; Amfilochiou, A.; Constantinidis, T.; Christaki, P., Greek version of the Epworth Sleepiness Scale. Sleep Breath, 2004, 8(2), 91-95.
47. Katsarou, Z.; Bostantjopoulou, S.; Hatzizisi, O.; Giza, E.; Soler-Cardona, A.; Kyriazis, G., [Immune factors or depression? Fatigue correlates in Parkinson's disease]. Rev. Neurol., 2007, 45(12), 725-728.
48. Stenton, C., The MRC breathlessness scale. Occup. Med. (Lond) 2008, 58(3), 226-227.
49. Kotronoulas, G. C.; Papadopoulou, C. N.; Papapetrou, A.; Patiraki, E., Psychometric evaluation and feasibility of the Greek Pittsburgh Sleep Quality Index (GR-PSQI) in patients with cancer receiving chemotherapy. Support Care Cancer, 2011, 19 (11), 1831-1840.
50. Parker, K. P.; Bliwise, D. L.; Ribeiro, M.; Jain, S. R.; Vena, C. I.; Kohles-Baker, M. K.; Rogatko, A.; Xu, Z.; Harris, W. B., Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J. Clin. Oncol., 2008, 26(15), 2464-2472.
51. Zarogoulidis, P., Darwiche, K., Kalamaras, G., Huang, H., Hohenforst-Schmidt, M., Zarogoulidis, K., Targeted versus chronotargeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer. Translational Lung Cancer Res., 2013, 2(1), E17-E22
52. Jean-Louis, G.; von Gizycki, H.; Zizi, F.; Fookson, J.; Spielman, A.; Nunes, J.; Fullilove, R.; Taub, H., Determination of sleep and wakefulness with the actigraph data analysis software (ADAS). Sleep, 1996, 19(9), 739-743.
53. Erren, T. C.; Reiter, R. J., Defining chronodisruption. J. Pineal. Res., 2009, 46 (3), 245-247
54. Mazzoccoli, G.; Tarquini, R.; Durfort, T.; Francois, J. C., Chronodisruption in lung cancer and possible therapeutic approaches. Biomed. Pharmacother., 2011, 65 (7), 500-508.
55. Gekakis, N.; Staknis, D.; Nguyen, H. B.; Davis, F. C.; Wilsbacher, L. D.; King, D. P.; Takahashi, J. S.; Weitz, C. J., Role of the CLOCK protein in the mammalian circadian mechanism. Science, 1998, 280(5369), 1564-1569.
56. Ancoli-Israel, S.; Rissling, M.; Neikrug, A.; Trofimenko, V.; Natarajan, L.; Parker, B. A.; Lawton, S.; Desan, P.; Liu, L., Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer, 2012, 20(6), 1211-1219
57. Librodo, P.; Buckley, M.; Luk, M.; Bisso, A., Chronotherapeutic drug delivery. J. Infus. Nurs., 2012, 35(5), 329-3234
58. Neikrug, A. B.; Rissling, M.; Trofimenko, V.; Liu, L.; Natarajan, L.; Lawton, S.; Parker, B. A.; Ancoli-Israel, S., Bright light therapy protects women from circadian rhythm desynchronization during chemotherapy for breast cancer. Behav. Sleep Med., 2012, 10(3), 202-216
59. Li, X. M.; Delaunay, F.; Dulong, S.; Claustrat, B.; Zampera, S.; Fujii, Y.; Teboul, M.; Beau, J.; Levi, F., Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res., 2010, 70(8), 3351-3360.
60. Horowitz, M.; Wilner, N.; Alvarez, W., Impact of Event Scale: a measure of subjective stress. Psychosom. Med., 1979, 41(3), 209-218.
61. Carver, C. S., You want to measure coping but your protocol's too long: consider the brief COPE. Int. J. Behav. Med., 1997, 4(1), 92-100.
62. Rudnicki, S. R.; Graham, J. L.; Habboushe, D. F.; Ross, R. D., Social support and avoidant coping: correlates of depressed mood during pregnancy in minority women. Women Health, 2001, 34(3), 19-34.
63. Lee, K. A., Self-reported sleep disturbances in employed women. Sleep, 1992, 15(6), 493-498.
64. Lee, K. A.; Hicks, G.; Nino-Murcia, G., Validity and reliability of a scale to assess fatigue. Psychiatry Res., 1991, 36(3), 291-298
65. Lee, K. A.; Lentz, M. J.; Taylor, D. L.; Mitchell, E. S.; Woods, N. F., Fatigue as a response to environmental demands in women's lives. Image J. Nurs. Sch., 1994, 26(2), 149-154.
66. Cimprich, B., Attentional fatigue following breast cancer surgery. Res. Nurs. Health, 1992, 15(3), 199-207.
67. Karnofsky, D. A., The bases for cancer chemotherapy. Stanford Med. Bull, 1948, 6 (1), 257-269.
68. Piper, B. F.; Dibble, S. L.; Dodd, M. J.; Weiss, M. C.; Slaughter, R. E.; Paul, S. M., The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol. Nurs. Forum, 1998, 25(4), 677-684.
69. Hearn, J.; Higginson, I. J., Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual. Health Care, 1999, 8(4), 219-227.
70. Portenoy, R. K.; Payne, D.; Jacobsen, P., Breakthrough pain: characteristics and impact in patients with cancer pain. Pain, 1999, 81(1-2), 129-134.
71. Sephton, S. E.; Lush, E.; Dedert, E. A.; Floyd, A. R.; Rebholz, W. N.; Dhabhar, F. S.; Spiegel, D.; Salmon, P., Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav. Immun., 2013, 30 Suppl, S163-S170
72. Xiang, S.; Mao, L.; Duplessis, T.; Yuan, L.; Dauchy, R.; Dauchy, E.; Blask, D. E.; Frasch, T.; Hill, S. M., Oscillation of clock and clock controlled genes induced by serum shock in human breast epithelial and breast cancer cells: regulation by melatonin. Breast Cancer (Auckl), 2012, 6, 137-150.
73. Tateishi, Y.; Kouyama, R.; Mihara, M.; Doi, M.; Yoshimoto, T.; Hirata, Y., Evaluation of salivary cortisol measurements for the diagnosis of subclinical Cushing's syndrome. Endocr. J., 2012, 59 (4), 283-289.
74. Mazzoccoli, G.; Sothern, R. B.; Parrella, P.; Muscarella, L. A.; Fazio, V. M.; Giuliani, F.; Polyakova, V.; Kvetnoy, I. M., Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls. Clin. Exp. Med., 2012, 12(3), 181-194.
75. Chen, R.; Yang, K.; Zhao, N. B.; Zhao, D.; Chen, D.; Zhao, C. R.; Tang, H., Abnormal expression of PER1 circadian-clock gene in oral squamous cell carcinoma. Onco. Targets Ther., 2012, 5, 403-407.
76. Gu, X.; Xing, L.; Shi, G.; Liu, Z.; Wang, X.; Qu, Z.; Wu, X.; Dong, Z.; Gao, X.; Liu, G.; Yang, L.; Xu, Y., The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ., 2012, 19(3), 397-405.
77. Mao, L.; Dauchy, R. T.; Blask, D. E.; Slakey, L. M.; Xiang, S.; Yuan, L.; Dauchy, E. M.; Shan, B.; Brainard, G. C.; Hanifin, J. P.; Frasch, T.; Duplessis, T. T.; Hill, S. M., Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3beta. Mol. Endocrinol., 2012, 26 (11), 1808-1820.
78. Narasimamurthy, R.; Hatori, M.; Nayak, S. K.; Liu, F.; Panda, S.; Verma, I. M., Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc. Natl. Acad. Sci. USA, 2012, 109 (31), 12662-12667.
79. Tamura, Y.; Matsuda, M.; Chiba, S., [Actigraphy in sleep medicine and sleep research]. Nihon Rinsho, 2009, 67(8), 1576-1580.
80. Gupta, D.; Shukla, P.; Munshi, A.; Aggarwal, J. P., Cardioprotective radiotherapy: the circadian way. Med. Hypotheses, 2012, 78(3), 353-355.
81. Saini, A.; Tucci, M.; Tampellini, M.; Maina, D.; Bouraouia, K.; Giuliano, P. L.; Termine, A.; Castellano, M.; Campagna, S.; Laciura, P.; Berruti, A., Circadian variation of breakthrough pain in cancer patients. Eur. J. Pain., 2013, 17(2), 264-270.
82. Okyar, A.; Piccolo, E.; Ahowesso, C.; Filipski, E.; Hossard, V.; Guettier, C.; La Sorda, R.; Tinari, N.; Iacobelli, S.; Levi, F., Strainand sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One, 2011, 6(6), e20393.
83. Ballesta, A.; Dulong, S.; Abbara, C.; Cohen, B.; Okyar, A.; Clairambault, J.; Levi, F., A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput. Biol., 2011, 7(9), e1002143.
84. Hu, Y.; Spengler, M. L.; Kuropatwinski, K. K.; Comas-Soberats, M.; Jackson, M.; Chernov, M. V.; Gleiberman, A. S.; Fedtsova, N.; Rustum, Y. M.; Gudkov, A. V.; Antoch, M. P., Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget, 2011, 2(12), 1279-1290.
85. Rayman, M. P., Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc. Nutr. Soc., 2005, 64(4), 527-542.
86. Yoshida, K.; Sato, M.; Hase, T.; Elshazley, M.; Yamashita, R.; Usami, N.; Taniguchi, T.; Yokoi, K.; Nakamura, S.; Kondo, M.; Girard, L.; Minna, J. D.; Hasegawa, Y., TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. Cancer Sci., 2013, 104(2), 171-177.
87. Weigl, Y.; Peleg, L.; Dotan, A.; Ashkenazi, I. E., Cisplatin effects on rhythmic functions of mice: strain and tissue dependence. Chronobiol. Int., 2012, 29(6), 724-735.
88. Iwata, K.; Aizawa, K.; Sakai, S.; Jingami, S.; Fukunaga, E.; Yoshida, M.; Hamada, A.; Saito, H., The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients. Biol. Pharm. Bull., 2011, 34(11), 1765-1768.
89. Innominato, P. F.; Focan, C.; Gorlia, T.; Moreau, T.; Garufi, C.; Waterhouse, J.; Giacchetti, S.; Coudert, B.; Iacobelli, S.; Genet, D.; Tampellini, M.; Chollet, P.; Lentz, M. A.; Mormont, M. C.; Levi, F.; Bjarnason, G. A., Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res., 2009, 69 (11), 4700-4707.
90. Innominato, P. F.; Giacchetti, S.; Bjarnason, G. A.; Focan, C.; Garufi, C.; Coudert, B.; Iacobelli, S.; Tampellini, M.; Durando, X.; Mormont, M. C.; Waterhouse, J.; Levi, F. A., Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int. J. Cancer, 2012, 131(11), 2684-2692.
91. Bouchahda, M.; Adam, R.; Giacchetti, S.; Castaing, D.; Brezault-Bonnet, C.; Hauteville, D.; Innominato, P. F.; Focan, C.; Machover, D.; Levi, F., Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer, 2009, 115(21), 4990-4999.
92. Sato, S.; Kigawa, J.; Irie, T.; Itamochi, H.; Kanamori, Y.; Kamazawa, S.; Akeshima, R.; Terakawa, N., Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer. Am. J. Clin. Oncol., 2002, 25(3), 289-290.
93. Lemmer, B., Relevance for chronopharmacology in practical medicine. Semin. Perinatol., 2000, 24(4), 280-290.
94. Bosquillon, C., Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci., 2010, 99 (5), 2240-2455.
95. Zarogoulidis, P.; Trakada, G.; Zarogoulidis, K., A chrono-target chemotherapy treatment model for lung cancer treatment. Ther. Deliv., 2013, 4(1), 5-8.
96. Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H., Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11(17-18), 812-818.
97. Bae, Y. H., Interview with Dr You Han Bae: ligand-mediated versus 'passive' targeting approaches in nanoparticle oncology research. Ther. Deliv., 2012, 3(8), 933-936.
98. Stylianopoulos, T., EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther. Deliv., 2013, 4(4), 421-423.
99. Kroz, M.; Reif, M.; Bussing, A.; Zerm, R.; Feder, G.; Bockelbrink, A.; von Laue, H. B.; Matthes, H. H.; Willich, S. N.; Girke, M., Does self-regulation and autonomic regulation have an influence on survival in breast and colon carcinoma patients? results of a prospective outcome study. Health Qual. Life Outcomes, 2011, 9, 85.